HENDERSON MICHAEL THOMAS 4

What Happened Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics (APGE), sold a total of 20,000 shares in open-market transactions on June 10, 2026, generating aggregate proceeds of approximately $1,667,621. The sales were executed in multiple lots:

• 6,770 shares at a weighted avg. price reported as $82.21 (proceeds ~$556,562)
• 7,654 shares at $82.78 (proceeds ~$633,598)
• 1,080 shares at $84.18 (proceeds ~$90,914)
• 1,577 shares at $85.19 (proceeds ~$134,345)
• 2,305 shares at $86.27 (proceeds ~$198,852)
• 614 shares at $86.89 (proceeds ~$53,350)

These were sales (transaction code S), which are often routine insider liquidity events rather than bullish signals.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely — within required filing window).
• Total shares sold: 20,000; total proceeds: ~$1,667,621.
• Price detail: each lot was sold in multiple executions; reported weighted-average prices correspond to price ranges (rough ranges reported in the filing: ~$81.57–$87.17 across the lots).
• Footnote: filing states the trades were executed pursuant to a Rule 10b5‑1 trading plan adopted August 13, 2025.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Transaction type: S = Sale.

Context Sales executed under a 10b5‑1 plan are pre‑scheduled trades that insiders establish in advance; they can reduce concerns about trading on material nonpublic information but do not necessarily reflect the insider’s current view of the company. For retail investors, purchases are generally more informative about insider sentiment than routine sales.